<DOC>
	<DOCNO>NCT00115518</DOCNO>
	<brief_summary>The purpose trial study combine locoregional radiotherapy cetuximab non-operable NSCLC Stage III ( Phase II trial ) . Endpoints : safety feasibility ( primary ) response , survival , time progression ( secondary )</brief_summary>
	<brief_title>Radiation Plus Cetuximab Locally Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Study entry examination : - blood cell count - liver enzymes - ventilatory function test - pregnancy test ( premenopausal woman ) - CT thorax - CT brain - Ultrasound liver - Bone scan - FDG PET scan ( inclusion ) Follow-up examination ( 2 month , every 3 month ) : - patient history examination - CT scan thorax - ventilatory function test - FDG PET scan ( least 6 month ) - bone scan ( yearly ) - ultrasound liver ( every 6 month ) Cetuximab administration : - 450 mg / m^2 body surface week 1 - 250 mg /m^2 body surface weekly , week 2 -21 Radiation therapy : - intensity modulate radiation therapy primary tumor mediastinum ( 2 Gy single dose , total dose 50 Gy ; 5 fraction per week ) boost PET positive site ( 2 Gy single dose 66 Gy ) . Radiation therapy week 2-8 . Amendment 1/07 : 3D conformal RT possible , FeV1 &lt; 1.5L &lt; 50 %</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically verify NSCLC Not eligible Radiochemotherapy patient refuse chemotherapy FeV1 &gt; 1.5 L min . 50 % KPI &gt; = 70 % Life expectancy &gt; 6 month Weight loss le 10 % body weight 12 month Compliance Adequate blood count ( LC &gt; 3000 x 10^3/ml , Tc &gt; 100000 x 10^3/ml , Hb &gt; 10 g/dl ) Effective contraception Amendment 1/07 : FeV1 &gt; 1.2 L min 40 % Active infection Reduced liver function Vena cava superior syndrome Malignant pleural effusion Pregnancy breast feed Additional serious systemic disease Secondary malignancy ( except carcinoma situ cervix , basalioma skin , secondary cancer remission &gt; 5 year ) Known allergy proteins History former antibody therapy Allergy i.v . contrast agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>